Abstract: |
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with impairment or infantile spasm. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs). |
Inventor: |
Guy, Geoffrey (Cambridge, GB); Wright, Stephen (Cambridge, GB); Devinsky, Orrin (New York, NY, US) |
Applicant: |
GW Pharma Limited (Cambridge, GB) |
Face Assignee: |
GW Research Limited (Cambridge, GB) |
Filed: |
2015-10-14 |
Issued: |
2020-09-08 |
Claims: |
15 |
|
US10765643
|
1. A method of treating seizures in a subject having Aicardi Syndrome, comprising administering to the subject in need thereof cannabidiol (CBD),
(7)
(1)
|
|
9. A method of treating seizures in a subject having Aicardi Syndrome, comprising administering to the subject in need thereof cannabidiol (CBD) at a dose ranging from 5 mg/kg/day to 25 mg/kg/day,
(6)
(1)
|
|